Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The goal of this observational study is to determine if electrophysiologic mapping and cardiac MRI can help identify patients that have genetic forms of cardiomyopathy that are at high risk for development of dangerous ventricular arrhythmias. The investigators aim to study: 1. the prevalence and mechanism of inducible ventricular tachycardia 2. pace-mapping to define the site of origin of ventricular arrhythmias 3. voltage mapping to define low voltage scar substrate in the basal LV to determine the risk of development of ventricular arrhythmias in patients with genetic forms of cardiomyopathy. Participants will undergo cardiac MRI before their scheduled procedure and voltage mapping during their scheduled procedure as part of data collection.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adults aged 18 and older

• Diagnosed with AF, frequent PVCs, or VT before age 60

• Scheduled for catheter-based AF ablation (de-novo or repeat) OR catheter-based PVC ablation OR catheter-based VT ablation

• Able to provide written, informed consent

• P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control.

Locations
United States
Tennessee
Vanderbilt University Medical Center
RECRUITING
Nashville
Contact Information
Primary
Dakota Graherr, RN
dakota.grauherr@vumc.org
615-936-6069
Time Frame
Start Date: 2023-12-13
Estimated Completion Date: 2029-12
Participants
Target number of participants: 200
Treatments
TTN-positive
Patients with a pathogenic or likely pathogenic variant in TTN on clinical genetic testing.
Gene-positive
Patients with a pathogenic or likely pathogenic variant in a gene other than TTN on clinical genetic testing.
Gene-negative
Patients without a pathogenic or likely pathogenic variant in a cardiomyopathy or arrhythmia gene on clinical genetic testing.
Sponsors
Leads: Vanderbilt University Medical Center

This content was sourced from clinicaltrials.gov